Skip to main content
OpenTrials
Completed

NCT Number: NCT00509808

Evaluation of an Electro-stimulator for the Treatment of Xerostomia

This is a multinational trial, aimed at testing the safety and performance of a electrostimulating device ("GenNarino") to treat dry mouth, over one year. The design is as follows:

* Multi-center, double blind, sham (placebo) controlled, about 10 xerostomia patients per center * Patients receive a GenNarino (and its remote control) that is programmed for one month sham and one month active mode (the order of which is randomly assigned), and thereafter 9 months at the active mode (divided in period of 3 months, the order of each is randomly assigned at wearing GenNarino for 1, 5 or 10 minutes at a time).

Study hypothesis: Gennarino will lead to significant symptomatic improvement

- At the clinic: monthly examinations at the first 2 months, and then every 3 months, including whole saliva collection and questionnaire; at the first visit impression taking for GenNarino preparation

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Helsinki University Central Hospital and University of Helsinki

Helsinki, 00014, Finland

About this study

The clinical trial, titled "Safety and performance evaluation of an electro-stimulator mounted on an intra-oral removable appliance (GenNarino) for the treatment of xerostomia" is a prospective, randomized, double-blind, sham-controlled multi-center trial, followed by an open-label study. Study subjects are patients with xerostomia. The purpose of the trial is to test the safety and efficacy of electrostimulation using the GenNarino device.

The primary endpoint is significant symptomatic improvement, and the secondary ones, increased salivary output and event free use (no adverse side-effects). The clinical follow-up consists of periodic clinical examinations.

In this clinical trial the use of the device is compared between active vs. sham mode for one month each in a double-blind design (Stage I). Thereafter, at Stage II the xerostomia relieving effect of the active device is assessed in an open label design for additional 6 months. Clinic- and home-based questionnaires and whole saliva collections are performed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient must be at least 18 years of age.
  • The patient must have clinical symptoms of xerostomia (dry mouth) due to
  • Primary or secondary Sjögren's syndrome
  • Medication intake
  • Head and neck radiation with survival expectancy of more than one year
  • Chronic graft vs. host disease with survival expectancy of more than one year
  • Patients are requested not to take systemic sialogogues during the first 2 months of the study (when active is tested vs. sham)
  • Female patients of child bearing potential must have a negative pregnancy test within twenty-four hours of enrollment.
  • The patient must understand and consent in writing to the procedure.
  • The patient agrees to undergo all examinations and clinical evaluations planned for the study.

Exclusion criteria

  • Active HIV or HCV infection
  • Severe systemic disease
  • Known allergy to materials similar to be used in the investigational product
  • Known mental disease
  • Presence of depression, by positive answers to both the following questions:
  • "During the past month have you often been bothered by feeling down, depressed or hopeless?"
  • "During the past month have you often been bothered by little interest or pleasure in doing things?"
  • Patients wearing other active implants like pacemaker or defibrillator
  • Patients with poor oral hygiene
  • Patients whose oral anatomical characteristics precludes the insertion of the device
  • Patients who are unable or unwilling to cooperate with study procedures.
  • Pregnancy
  • Presence of erosive or ulcerative oral lesions, which are chronic or recurrent, such as erosive lichen planus, RAS, eryth. Candidosis, and of suspected pre-malignant or malignant lesions

Treatment and study plan

Electrostimulation

Device
  • 1st month GN wearing (activated or sham mode)
  • 2nd month wearing (opposite mode)
  • 3rd - 5th month: activated GN wearing for 1, 5 or 10 minutes
  • 6th - 8th month: activated GN wearing for 1, 5 or 10 minutes
  • 9th - 11th month: activated GN wearing for 1, 5 or 10 minutes

Other names: GenNarino

Primary outcomes

  1. Significant symptomatic improvement

    Time frame: 1 year

Secondary outcomes

  1. 1- Increased salivary output 2- Event free use (no adverse side-effects)

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Saliwell Ltd.

Industry

Collaborators

  • Charite University, Berlin, Germany
  • Hebrew University of Jerusalem
  • Hospital San Carlos, Madrid
  • Indiana University
  • Istanbul University
  • McGill University
  • Skane University Hospital
  • Universidad El Bosque, Bogotá
  • Universidad Nacional Autonoma de Mexico
  • Universita degli Studi di Palermo
  • University of Brasilia
  • University of Helsinki
  • University of Kentucky
  • University of Zagreb

Registry information

Official study title

Safety and Performance Evaluation of an Electro-stimulator Mounted on an Intra-oral Removable Appliance (Saliwell GenNarino) for the Treatment of Xerostomia

Acronym: GenNarino

Important dates

Study start
2007
Primary completion
2008
Study completion
2010
First posted
Aug 1, 2007
Registry last updated
Apr 6, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.